Fagron N.V. : Case intact
>2H20 results not that exciting, driven by pandemic - Fagron reported FY20 results that were not overly exciting (REBITDA 1% below consensus). EMEA (flat vs 1H20) and Latin-American (down slightly) margins were impacted by a combination of the continued postponement of (higher-margin) elective care treatments and (often as a result) unfavourable product/mix.Fagron bullish on recovery, which should kick in by 2Q-3Q21 - During the FY20 conference call, ...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.